AIM
Neurofibromatosis type 1 (NF1) is a genetic disorder with a cognitive profile that includes visual–spatial perception deficits and a high incidence of reading disability. There is a paucity of information about how this cognitively complex population responds to mainstream reading interventions. The clinical trial goals were to determine whether children and adolescents with NF1 and reading deficits (NF+RD) benefit from mainstream remedial reading programs and whether responsiveness varies with differences in program-related visual–spatial demands.
METHOD
Forty-nine participants (18 males, 21 females; aged 8–14y) with either NF+RD (n=17, 11 males, 6 females) or idiopathic reading deficit (IRD) (n=32, 17 males, 15 females) were randomly assigned to intensive remedial teaching using one of two multisensory reading programs: one with greater kinesthetic demands and the other with greater visual–spatial demands. Two control groups – wait-list IRD (n=14, 11 males, 3 females) and typically developing readers (n=26, 13 males, 13 females) – received no treatment. Repeated measures and multivariate ANOVA analyses compared each group's growth in reading achievement from pre- to post-testing.
RESULTS
Treated groups showed significant growth whereas untreated groups did not. Comparing treated groups, the IRD group responded equally well to both interventions, whereas the NF+RD group showed a better response to the more kinesthetic approach.
INTERPRETATION
Results suggest that multisensory remedial reading teaching that emphasizes kinesthetic demands more than visual–spatial demands is suitable for students with NF+RD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.